121 filings
Page 2 of 7
8-K
8fdyzvusi321iv8wj9
14 Mar 23
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
7:32am
8-K
0jswy
7 Feb 23
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
4:20pm
8-K
6a2t77yh tpk
9 Jan 23
January 2023 Larimar Therapeutics Corporate Presentation
4:03pm
8-K
s669sz78syxx
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
78hj1iz6arvh
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
e44yiv6rlj0rt7f
14 Sep 22
Entry into a Material Definitive Agreement
9:01am
8-K
1w7wq
14 Sep 22
Other Events
7:05am
8-K
il5nlcuhezk5ao
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
r67vs0wpn xj120
12 May 22
Departure of Directors or Certain Officers
4:10pm
8-K
3fz8mf7vn9
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
hobih8ebd4f06 9z2u
11 Apr 22
Departure of Directors or Certain Officers
4:06pm
8-K
2ptv ut9vt63y
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
h3xefn4kjt18wgg0
28 Feb 22
Results of Operations and Financial Condition
8:16am
8-K
gzwlq19a9hg
14 Feb 22
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
12:00am
8-K
10hu06du2lw1pb
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
8-K
8ojalwhhv
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
erab8i3wbl31i
1 Jul 21
Other Events
6:11am
8-K
tf6ey
14 Jun 21
Other Events
5:21pm
8-K
o6bh3
26 May 21
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
10:17am
8-K
0k652e6 ih1f6
21 May 21
Entry into a Material Definitive Agreement
9:30am